These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 28124664)
1. Screening for renal involvement in ANCA-associated vasculitis: room for improvement? Houben E; van der Heijden JW; van Dam B; Bax WA; Voskuyl AE; Penne EL Neth J Med; 2017 Jan; 75(1):21-26. PubMed ID: 28124664 [TBL] [Abstract][Full Text] [Related]
2. Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. Manenti L; Vaglio A; Gnappi E; Maggiore U; Allegri L; Allinovi M; Urban ML; Delsante M; Galetti M; Nicastro M; Pilato FP; Buzio C Clin J Am Soc Nephrol; 2015 Dec; 10(12):2143-51. PubMed ID: 26542163 [TBL] [Abstract][Full Text] [Related]
3. [Kidney injury molecules (KIM-1, MCP-1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibody-associated glomerulonephritis]. Bulanov NM; Serova AG; Kuznetsova EI; Bulanova ML; Novikov PI; Kozlovskaya LV; Moiseev SV Ter Arkh; 2017; 89(6):48-55. PubMed ID: 28745689 [TBL] [Abstract][Full Text] [Related]
4. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study. García L; Pena CE; Maldonado RÁ; Costi C; Mamberti M; Martins E; García MA Clin Rheumatol; 2019 Oct; 38(10):2819-2824. PubMed ID: 31222573 [TBL] [Abstract][Full Text] [Related]
5. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: a comparative study. Chen YX; Zhang W; Chen XN; Yu HJ; Ni LY; Xu J; Pan XX; Ren H; Chen N J Rheumatol; 2012 Mar; 39(3):558-63. PubMed ID: 22247359 [TBL] [Abstract][Full Text] [Related]
7. [Retrospective clinical features and renal pathological analysis of 15 children with anti-neutrophil cytoplasmic antibody-associated vasculitis]. Guan N; Yao Y; Yang JY; Xiao HJ; Ding J Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):283-7. PubMed ID: 23927802 [TBL] [Abstract][Full Text] [Related]
8. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. Mohammad AJ; Segelmark M J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836 [TBL] [Abstract][Full Text] [Related]
9. Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis. Clerte M; Philip R; Levi C; Cornec-Le Gall E; Audard V; Huart A; Puéchal X; Touzot M; Rabot N; Thervet É; Aouba A; Karras A Scand J Rheumatol; 2022 May; 51(3):205-213. PubMed ID: 34169779 [TBL] [Abstract][Full Text] [Related]
10. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis. Chen YX; Zhang W; Chen XN; Ni LY; Shen PY; Wang WM; Chen N Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S5-10. PubMed ID: 24480250 [TBL] [Abstract][Full Text] [Related]
14. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Sinico RA; Di Toma L; Radice A Autoimmun Rev; 2013 Feb; 12(4):477-82. PubMed ID: 22921791 [TBL] [Abstract][Full Text] [Related]
15. Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis. Wu L; Li XQ; Goyal T; Eddy S; Kretzler M; Ju WJ; Chen M; Zhao MH Ann Rheum Dis; 2018 Sep; 77(9):1339-1344. PubMed ID: 29724728 [TBL] [Abstract][Full Text] [Related]
16. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Dekkema GJ; Abdulahad WH; Bijma T; Moran SM; Ryan L; Little MA; Stegeman CA; Heeringa P; Sanders JF Nephrol Dial Transplant; 2019 Feb; 34(2):234-242. PubMed ID: 29506265 [TBL] [Abstract][Full Text] [Related]
17. Metabolomics combined with clinical analysis explores metabolic changes and potential serum metabolite biomarkers of antineutrophil cytoplasmic antibody-associated vasculitis with renal impairment. Liu S; Xu Q; Wang Y; Lv Y; Liu QQ PeerJ; 2023; 11():e15051. PubMed ID: 36942002 [TBL] [Abstract][Full Text] [Related]
18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC; J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429 [TBL] [Abstract][Full Text] [Related]
19. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Ishizaki J; Takemori A; Suemori K; Matsumoto T; Akita Y; Sada KE; Yuzawa Y; Amano K; Takasaki Y; Harigai M; Arimura Y; Makino H; Yasukawa M; Takemori N; Hasegawa H; Arthritis Res Ther; 2017 Sep; 19(1):218. PubMed ID: 28962592 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Hu W; Liu C; Xie H; Chen H; Liu Z; Li L Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]